Hims & Hers Health, Inc. Class A Common Stock (HIMS)

16.62
-0.43 (-2.52%)
NYSE · Last Trade: Nov 19th, 10:10 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close17.05
Open17.20
Bid16.60
Ask16.63
Day's Range16.61 - 17.28
52 Week Range13.74 - 40.99
Volume2,209,488
Market Cap3.19B
PE Ratio (TTM)-20.02
EPS (TTM)-0.8
Dividend & YieldN/A (N/A)
1 Month Average Volume14,670,520

Chart

About Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More

News & Press Releases

Beyond GLP-1: The Next Wave of Peptide Innovation Could Unlock Billions in Biotech Growth
GLP-1 Treatments, Anticancer Research, and Emerging Therapeutic Technologies Are Driving the Next Chapter of Pharmaceutical Innovation
By FN Media · Via GlobeNewswire · November 19, 2026
Beyond GLP-1: The Next Wave of Peptide Innovation Could Unlock Billions in Biotech Growth
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:LLY),(NYSE:HIMS),(TSXV:PAIN),(CSE:VLAB) EQNX::TICKER_END
Via FinancialNewsMedia · November 19, 2026
Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health
Hims & Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC-157 and TB-500 will follow, consistent with regulatory standards.
By Hims & Hers · Via Business Wire · November 18, 2026
Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?fool.com
The company generated strong growth last quarter, but its bottom line didn't look nearly as impressive.
Via The Motley Fool · November 16, 2026
Why Is Hims Stock Crashing, and is it a Buying Opportunity?fool.com
Revenue is increasing, but so are its operating expenses.
Via The Motley Fool · November 14, 2026
Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?fool.com
Hims & Hers stock crashed after issuing weak guidance.
Via The Motley Fool · November 13, 2026
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Offmarketbeat.com
Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.
Via MarketBeat · November 12, 2026
A $400 Billion Healthcare Opportunity: Telehealth Companies Positioned to Capitalize on a Massive Industry Shift
Healthcare Innovation and Technology Adoption Are Reshaping How Millions of Patients Access Medical Services
By FN Media · Via GlobeNewswire · November 11, 2026
A $400 Billion Healthcare Opportunity: Telehealth Companies Positioned to Capitalize on a Massive Industry Shift
EQNX::TICKER_START (OTCQB:AIRDF),(CSE:AIDR),(NYSE:TDOC),(NYSE:AMWL),(NYSE:HIMS),(NYSE:DOCS) EQNX::TICKER_END
Via FinancialNewsMedia · November 11, 2026
Why Hims & Hers Health (HIMS) shares are getting obliterated today
What happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 18.5% in the afternoon session after the company reported its financial resul...
Via StockStory · November 10, 2026
Hims & Hers: 3 Key Takeaways for Long-Term Investorsfool.com
Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.
Via The Motley Fool · November 10, 2026
Stock Market Today: Nvidia Board Opens Probe Into Jensen Huang as Wall Street Licks Its AI Woundschartmill.com
Via Chartmill · November 10, 2026
Hims & Hers (HIMS) Q3 2026 Earnings Call Transcriptfool.com
International expansion offset a U.S. subscriber slowdown in the quarter.
Via The Motley Fool · November 10, 2026
HIMS Q3 2026 deep dive: cautious marketing spend and product launches shape guidance
Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q3 2026, with sales up 48.6% year on year to $890.4 million. On t...
Via StockStory · November 10, 2026
What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Callmarketbeat.com
Hims & Hers Health (NYSE:HIMS) reported third-quarter revenue growth of 49% but lost 100,000 subscribers from the prior quarter, as the digital health company held back U.S. weight-loss marketing and consolidated brands in international markets. Revenue rose to $890 million, while subscribers i
Via MarketBeat · November 10, 2026
Hims & Hers Health (NYSE:HIMS) posts Q3 2026 sales in line with estimates but full-year sales guidance misses expectations
Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q3 2026, with revenue up 48.6% year on year to $890.4 million. On...
Via StockStory · November 9, 2026
Dr. Andrew Huberman Joins Hims & Hers Board of Directors
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the company’s Board of Directors.
By Hims & Hers · Via Business Wire · November 9, 2026
Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended September 30, 2026.
By Hims & Hers · Via Business Wire · November 9, 2026
Hims & Hers Health earnings: what to look for from HIMS
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings this Monday after market close. Here’s what you need to know. Hims & Hers Health...
Via StockStory · November 7, 2026
Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?fool.com
Both are disruptors, but one of these growth stocks stands out over the other.
Via The Motley Fool · November 6, 2026
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.
By Hims & Hers · Via Business Wire · November 6, 2026
Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watchmarketbeat.com
Via MarketBeat · November 5, 2026
Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide Market
New HHS Direction Creates Potential Opportunities for Peptide Manufacturers, Biotech Companies, and Healthcare Innovators
By FN Media · Via GlobeNewswire · November 5, 2026
Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NASDAQ:MBX),(NASDAQ:KLRA),(NASDAQ:ALT),(NYSE:HIMS) EQNX::TICKER_END
Via FinancialNewsMedia · November 5, 2026
Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits: Grüns®, Medjet®, Tonal™, and Viome™. The program launched in March with two partners and has grown to include 14, with benefits designed to support subscribers’ whole-body health, including through a GLP-1 weight loss journey.
By Hims & Hers · Via Business Wire · November 5, 2026